Streetbeat News

Earnings

ADCT

ADC Therapeutics (NYSE:ADCT) reported Q3 adjusted losses of $(0.41) per share, beating the analyst consensus estimate of $(0.63) by 34.92%. However, the company's quarterly sales of $14.49 million missed the analyst consensus estimate of $15.99 million by 9.36%. This represents a 415.38% decrease in earnings and an 81.01% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:13 pm

CECO

CECO Environmental has raised its FY23 outlook, now expecting revenue between $525M-$550M, up approximately 25% YoY, and adjusted EBITDA between $55M-$57M, up approximately 33% YoY. This is an increase from the previous outlook provided in September, which expected revenues to exceed $525M and adjusted EBITDA to exceed $55M.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:12 pm

STOK

Stoke Therapeutics reported Q3 losses of $(0.55) per share, beating the analyst consensus estimate of $(0.63) by 12.7%. This is a 16.67% increase over losses from the same period last year. The company also reported quarterly sales of $3.31 million, beating the analyst consensus estimate of $3.19 million by 3.70%. This is a 13.87% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:12 pm

ADV

Advantage Solutions has updated its FY23 outlook, expecting Adjusted EBITDA to be around the upper end of the guidance range of $400 million to $420 million. This includes the impact of completed divestitures and anticipates continued pricing realization, growth in in-store sampling and demonstration events, and further investments in technology and talent.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:11 pm

NOVT

Novanta has revised its FY23 GAAP revenue forecast to $878M-$882M, down from the previous estimate of $892M-$902M and below the $899.33M market estimate. The company also adjusted its FY23 diluted EPS forecast to $2.98-$3.05, slightly below the $3.08 market estimate but within the previous range of $2.96-$3.15.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:11 pm

GFS

GlobalFoundries has released its Q4 2023 guidance, expecting revenues of $1.825B-$1.875B, slightly below the estimated $1.89B. The company also anticipates an adjusted EPS of $0.53-$0.64, surpassing the estimated $0.52.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:11 pm

IMCR

Immunocore Hldgs (NASDAQ:IMCR) reported Q3 earnings of $0.04 per share, a 69.23% decrease YoY. The company's quarterly sales were $60.73M, missing the analyst consensus estimate of $62.14M by 2.27%, but representing a 32.39% increase YoY.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:10 pm

ADV

Advantage Solutions (NASDAQ:ADV) reported Q3 GAAP EPS of $(0.07), a 200% decrease YoY, and sales of $1.10B, missing the estimate by 0.36%. This is a 4.27% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:10 pm

GILT

Gilat Satellite Networks (NASDAQ:GILT) reported Q3 earnings of $0.08 per share, beating the analyst consensus estimate of $0.04 by 100%. However, the company's quarterly sales of $63.90 million missed the analyst consensus estimate of $67.94 million by 5.94%.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:10 pm

VST

Vistra Corp. has projected its FY24 adjusted EBITDA to be between $3.7 billion and $4.1 billion.

Portfolio Pulse from Benzinga Newsdesk

November 07, 2023 | 12:09 pm